In particular, the anti-PD-L1 antibody-induced increase in EVs from mutant EGFR cells could have broad ranging effects on the tumor microenvironment and tumor immune landscape that could contribute to resistance to immunotherapy [56, 57]. Here, CD274 is linked to neoplasm.